small proline rich protein 1BGenealiases: CORNIFIN · GADD33 · SPR-IB · SPRR1
Q-omics provides the consensus-scored SPRR1B profile across patient tissues and cancer cell-line models. SPRR1B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SPRR1B is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, SPRR1B protein abundance shows 12,619 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight SKCM, LUAD, and HNSC as cancer lineages where SPRR1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPRR1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPRR1B survival associations across molecular data types. SPRR1B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPRR1B RNA expression–survival associations across cancer types. High SPRR1B expression shows unfavorable associations in SKCM, PAAD, BLCA, LUAD, LIHC and COAD. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SPRR1B RNA expression.
This table summarizes SPRR1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SPRR1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPRR1B shows higher tumor expression in LUAD, COAD, LUSC, BLCA, PAAD and THCA. The LUAD box plot shows higher SPRR1B RNA expression in tumor versus normal tissue (log2 FC = +3.588, t-test p < 0.001).
This table shows molecular features associated with SPRR1B in patient tissues and cancer cell lines. In patient samples, SPRR1B shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPRR1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
